Zydus Lifesciences, formerly known as Cadila Healthcare, is a significant Indian pharmaceutical company with a global presence. The company maintains a vertically integrated business model, encompassing the entire pharmaceutical value chain from research and development to manufacturing and marketing of a diverse range of products, including generics, specialty formulations, biosimilars, vaccines, and APIs. Zydus has strategically focused on complex generics and specialty segments, including injectables and transdermals, to drive growth in regulated markets like the US. It also has a substantial presence in emerging markets. The company emphasizes innovation with a strong R&D pipeline, including novel chemical entities and biosimilars, reflecting its commitment to addressing unmet medical needs. Zydus continues to pursue both organic growth through new product launches and market expansion, and inorganic growth via strategic acquisitions to strengthen its market position and expand its therapeutic offerings. Operational efficiency and maintaining quality standards across its manufacturing facilities are also key priorities for the company.